Wire · founder news, decoded · technology
How FDA's PreCheck Pilot Aims to Speed Up US Drug Manufacturing
FDA has launched a PreCheck Pilot Program selecting seven pharma companies and CDMOs to build new US-based drug manufacturing facilities with earlier regulatory engagement and a more predictable approval path. Participants must commit to three years of manufacturing post-approval, with priority given to facilities addressing drug shortages and supply-chain vulnerabilities.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you're a CDMO or contract manufacturer, the FDA just created a fast-track window to build US capacity with predictable timelines—but you need to move now, as only seven slots were handed out and the commitment is binding for three years. Call customers with shortages or critical supply vulnerabilities this week; they're the ones the pilot prioritises.
Read the full story at chemanager-online.com →
Topics: Digital Health · fda-precheck-pilot · us-manufacturing-incentive · drug-shortages · regulatory-predictability · cdmo-opportunity